Literature DB >> 20049870

The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation.

Rosalinda Sorrentino1, Silvana Morello, Shuang Chen, Eduardo Bonavita, Aldo Pinto.   

Abstract

Toll-like receptors (TLRs) are related to foam cell formation (FCF), key event in the establishment/progression of atherosclerosis. The activation of TLR2 and TLR4 can increase FCF. The aim of this study was to evaluate the role of TLR9 in FCF. Murine macrophages were treated with CpG-ODN, TLR9 agonist, and oxidized particles of LDL (Paz-PC) and FCF was analyzed by means of Oil Red O staining. The administration of CpG-ODN plus Paz-PC onto macrophages increased the amount of lipid droplets, correlated to increased levels of tumor necrosis factor (TNF)-alpha, IFNbeta, and IP-10. The underlying mechanism by which TLR9 ligation influenced Paz-PC in the FCF was NF-kappaB- and IRF7-dependent, as observed by higher levels of phosphorylated IkappaBalpha, increased nuclear translocation of the p65 subunit, lower levels of the total IKKalpha protein and higher release of interferon-dependent cytokines, such as IP-10. Liver X receptors (LXRs) regulate lipid cellular transport and negatively modulate TLR-dependent signaling pathways. Indeed, the addition of GW3965, synthetic LXRs agonist, significantly reduced FCF after CpG-ODN plus Paz-PC stimulation. In this condition, we observed decreased levels of the nuclear translocation of the p65 subunit, related to the higher presence of LXRalpha into the nucleus. TNF-alpha, IP-10, and IFNbeta levels were reduced by the administration of GW3965 following CpG-ODN and Paz-PC treatment. In conclusion, the activation of TLR9 facilitates the formation of foam cells in an NF-kappaB- and IRF7-dependent manner, countered by the activation of LXRs. This study further support LXRs as potential anti-atherosclerotic target. J. Cell. Physiol. 223: 158-167, 2010. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049870     DOI: 10.1002/jcp.22022

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  17 in total

Review 1.  The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Authors:  Ying Zhou; Peter J Little; Liam Downey; Rizwana Afroz; Yuao Wu; Hang T Ta; Suowen Xu; Danielle Kamato
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-06

Review 2.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

3.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

Review 4.  The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis.

Authors:  Mohsin H K Roshan; Amos Tambo; Nikolai P Pace
Journal:  Int J Inflam       Date:  2016-10-04

5.  Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice.

Authors:  Alexander O Krogmann; Enzo Lüsebrink; Martin Steinmetz; Tobias Asdonk; Catharina Lahrmann; Dieter Lütjohann; Georg Nickenig; Sebastian Zimmer
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 6.  Emerging roles of Toll-like receptor 9 in cardiometabolic disorders.

Authors:  Sachiko Nishimoto; Daiju Fukuda; Masataka Sata
Journal:  Inflamm Regen       Date:  2020-07-21

7.  Activation of TRPV1 prevents OxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages: role of liver X receptor α.

Authors:  Jin-Feng Zhao; Li-Chieh Ching; Yu Ru Kou; Shing-Jong Lin; Jeng Wei; Song-Kun Shyue; Tzong-Shyuan Lee
Journal:  Mediators Inflamm       Date:  2013-06-26       Impact factor: 4.711

8.  Electronic Cigarettes Induce Mitochondrial DNA Damage and Trigger TLR9 (Toll-Like Receptor 9)-Mediated Atherosclerosis.

Authors:  Jieliang Li; Luong Huynh; William D Cornwell; Moon-Shong Tang; Hannah Simborio; Jing Huang; Beata Kosmider; Thomas J Rogers; Huaqing Zhao; Michael B Steinberg; Le Thu Thi Le; Lanjing Zhang; Kien Pham; Chen Liu; He Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-31       Impact factor: 10.514

9.  Toll-Like Receptor 9 Inactivation Alleviated Atherosclerotic Progression and Inhibited Macrophage Polarized to M1 Phenotype in ApoE-/- Mice.

Authors:  Chunmei Ma; Qiufang Ouyang; Ziyang Huang; Xiaoqing Chen; Ye Lin; Weiping Hu; Ling Lin
Journal:  Dis Markers       Date:  2015-07-15       Impact factor: 3.434

Review 10.  RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy.

Authors:  Wioletta Olejarz; Dominika Łacheta; Alicja Głuszko; Ewa Migacz; Wojciech Kukwa; Mirosław J Szczepański; Piotr Tomaszewski; Grażyna Nowicka
Journal:  Biomed Res Int       Date:  2018-08-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.